FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387379610> ?p ?o ?g. }

• W4387379610 abstract "Abstract Disclosure: S. Bendaram: None. P.J. Bhatt: None. V. Kantorovich: None. Background: The Human monoclonal antibody, Denosumab is a widely used antiresorptive therapy for Osteoporosis, which in the presence of risk factors can lead to hypocalcemia. We present an interesting case of severe and prolonged hypocalcemia due to Denosumab therapy, due to Vitamin D deficiency from malabsorption, despite the presence of undiagnosed Primary Hyperparathyroidism (PHPT). Case Presentation: 74-year old white female with a history of Crohn’s disease s/p ileostomy, Osteoporosis on Denosumab, Seizure disorder on Divalproex, and Parkinson’s disease presented to the ED for worsening altered mental status and decreased oral intake for at least 2 weeks prior to admission. On presentation, she was alert, oriented to person only, complaining of body aches. She was on no vitamin D supplements. Vital signs were unremarkable except for low BMI of 17.05 kg/m2. Physical exam revealed a chronic upper extremity tremor and a new facial mouth tremor associated with bruxism. Chvostek and Trousseau signs were negative, however this was after 1 dose of IV calcium gluconate in the ED. On presentation, initial labs revealed total calcium of 5.3 mg/dL [8.7-10.5], Albumin 4.7 g/dL [3.4-4.8], Magnesium 1.2 mg/dL [1.6-2.7], creatinine 1.5 mg/dL [04-1.1] (baseline 1.0). Further testing showed ionized calcium of 0.56 mmol/L [1.17-1.33], 25 Hydroxy Vitamin D 9 ng/mL [30-100], PTH 777 pg/mL [15-65] and phosphorus 3.6 mg/dL [2.7-4.5]. She was treated with IV calcium gluconate, 50,000 IU weekly vitamin D3 and calcium citrate 950mg oral BID, followed by which her total calcium went up to 12 mg/dl, with ionized calcium elevated at 1.36 mmol/L, while herPTH levels stayed inappropriately normal at 55 pg/ml. On the day of discharge, 25-OH-Vitamin D was 15 ng/dl, PTH 222 pg/ml and ionized calcium 1.07 mmol/L, when she was alert, oriented, with resolution of bone pains. Conclusion: Hypercalcemia in PHPT is from activation of osteoclasts and when these cells are inhibited by antiresorptive therapy, intestinal absorption will remain the primary source of plasma calcium levels. This explains the severe and prolonged hypocalcemia caused by Denosumab owing to its mechanism of action and long elimination half life, in our patient with Vitamin D deficiency on the background of malabsorption, despite a combination of primary and secondary elevation of PTH. Careful baseline assessment of calcium and Vitamin D levels, along with adequate supplementation and regular monitoring should be undertaken in all patients treated with Denosumab to avoid this. Presentation: Saturday, June 17, 2023" @default.
• W4387379610 created "2023-10-06" @default.
• W4387379610 creator A5001262116 @default.
• W4387379610 creator A5050746097 @default.
• W4387379610 creator A5083887576 @default.
• W4387379610 date "2023-10-01" @default.
• W4387379610 modified "2023-10-16" @default.
• W4387379610 title "SAT228 Denosumab Associated Severe Hypocalcemia Due To Vitamin D Deficiency In A Patient With Undiagnosed Primary Hyperparathyroidism" @default.
• W4387379610 doi "https://doi.org/10.1210/jendso/bvad114.524" @default.
• W4387379610 hasPublicationYear "2023" @default.
• W4387379610 type Work @default.
• W4387379610 citedByCount "0" @default.
• W4387379610 crossrefType "journal-article" @default.
• W4387379610 hasAuthorship W4387379610A5001262116 @default.
• W4387379610 hasAuthorship W4387379610A5050746097 @default.
• W4387379610 hasAuthorship W4387379610A5083887576 @default.
• W4387379610 hasBestOaLocation W43873796101 @default.
• W4387379610 hasConcept C124490489 @default.
• W4387379610 hasConcept C126322002 @default.
• W4387379610 hasConcept C134018914 @default.
• W4387379610 hasConcept C187212893 @default.
• W4387379610 hasConcept C2775945674 @default.
• W4387379610 hasConcept C2776286101 @default.
• W4387379610 hasConcept C2776541429 @default.
• W4387379610 hasConcept C2778049618 @default.
• W4387379610 hasConcept C2779053571 @default.
• W4387379610 hasConcept C2779740938 @default.
• W4387379610 hasConcept C2780439177 @default.
• W4387379610 hasConcept C71924100 @default.
• W4387379610 hasConcept C90924648 @default.
• W4387379610 hasConceptScore W4387379610C124490489 @default.
• W4387379610 hasConceptScore W4387379610C126322002 @default.
• W4387379610 hasConceptScore W4387379610C134018914 @default.
• W4387379610 hasConceptScore W4387379610C187212893 @default.
• W4387379610 hasConceptScore W4387379610C2775945674 @default.
• W4387379610 hasConceptScore W4387379610C2776286101 @default.
• W4387379610 hasConceptScore W4387379610C2776541429 @default.
• W4387379610 hasConceptScore W4387379610C2778049618 @default.
• W4387379610 hasConceptScore W4387379610C2779053571 @default.
• W4387379610 hasConceptScore W4387379610C2779740938 @default.
• W4387379610 hasConceptScore W4387379610C2780439177 @default.
• W4387379610 hasConceptScore W4387379610C71924100 @default.
• W4387379610 hasConceptScore W4387379610C90924648 @default.
• W4387379610 hasIssue "Supplement_1" @default.
• W4387379610 hasLocation W43873796101 @default.
• W4387379610 hasOpenAccess W4387379610 @default.
• W4387379610 hasPrimaryLocation W43873796101 @default.
• W4387379610 hasRelatedWork W2012165652 @default.
• W4387379610 hasRelatedWork W2017750101 @default.
• W4387379610 hasRelatedWork W2025604347 @default.
• W4387379610 hasRelatedWork W2033076468 @default.
• W4387379610 hasRelatedWork W2036082237 @default.
• W4387379610 hasRelatedWork W2065962239 @default.
• W4387379610 hasRelatedWork W2081828584 @default.
• W4387379610 hasRelatedWork W2399692849 @default.
• W4387379610 hasRelatedWork W2419223746 @default.
• W4387379610 hasRelatedWork W2475051989 @default.
• W4387379610 hasVolume "7" @default.
• W4387379610 isParatext "false" @default.
• W4387379610 isRetracted "false" @default.
• W4387379610 workType "article" @default.